[1] Vartak N, Damle-Vartak A, Richter B, et al. Cholestasis-induced adaptive remodeling of interlobular bile ducts. Hepatology, 2016, 63: 951-964.
[2] Naugler WE, Tarlow BD, Fedorov LM, et al. Fibroblast growth factor signaling controls liver size in mice with humanized livers. Gastroenterology, 2015, 149: 728-740 e15.
[3] Uriarte I, Latasa MU, Carotti S, et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer, 2015, 136: 2469-2475.
[4] Tabibian JH, O'Hara SP, Trussoni CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology, 2016, 63: 185-196.
[5] Joyce SA, MacSharry J, Casey PG, et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Nat Acad Sci USA,2014, 111: 7421-7426.
[6] Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun, 2015, 6: 10166.
[7] Sommerfeld A, Reinehr R, Haussinger D. Tauroursodeoxycholate protects rat hepatocytes from bile acid-induced apoptosis via beta1-integrin- and protein kinase a-dependent mechanisms. Cell Physiol Biochem, 2015, 36: 866-883.
[8] Keitel V, Reich M, Haussinger D. TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis? Clin Rev Allergy Immunol, 2015, 48: 218-225.
[9] Li T, Francl JM, Boehme S, et al. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J Biol Chem, 2012, 287: 1861-1873.
[10] Slijepcevic D, Kaufman C, Wichers CG, et al. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice. Hepatology, 2015, 62: 207-219.
[11] Dawson PA. Toxic bile and sclerosing cholangitis: Is there a role for pharmacological interruption of the bile acid enterohepatic circulation? Hepatology, 2016, 63: 363-364.
[12] Quraishi MN, Sergeant M, Kay G, et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut, 2016, pri: gutjnl-2016-311915.
[13] Munoz-Garrido P, Marin JJ, Perugorria MJ, et al. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol, 2015, 63: 952-961.
[14] Trauner M, Halilbasic E, Claudel T, et al. Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig Dis, 2015, 33: 433-439. |
